Correlation between the high expression levels of cancer-germline genes with clinical characteristics in esophageal squamous cell carcinoma.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Histology and Histopathology

• Publication date

  2017-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.14670/HH-11-847PMID 27868181
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer

  2016cited by this paper
• Expression of MAGE-A1-A12 subgroups in the invasive tumor front and tumor center in oral squamous cell carcinoma.

  2016cited by this paper
• Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers

  2016cited by this paper
• Anticancer effects of adenovirus-mediated calreticulin and melanoma-associated antigen 3 expression on non-small cell lung cancer cells.

  2015cited by this paper
• Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor*

  2015cited by this paper
• NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

  2015cited by this paper
• Peptide Splicing in the Proteasome Creates a Novel Type of Antigen with an Isopeptide Linkage

  2015cited by this paper
• Expression and antibody generation of the cancer-testis antigen, BIOT2-S.

  2015cited by this paper
• Epigenetic inactivation of SPINT2 is associated with tumor suppressive function in esophageal squamous cell carcinoma.

  2014influential reference
• Identification of genomic alterations in oesophageal squamous cell cancer

  2014cited by this paper
• Oesophageal squamous cell cancer: induction chemotherapy and oesophagectomy versus induction chemotherapy and chemoradiotherapy - a feasibility study

  2014cited by this paper
• Epitope distribution in ordered and disordered protein regions. Part B - Ordered regions and disordered binding sites are targets of T- and B-cell immunity.

  2014cited by this paper
• MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis

  2014cited by this paper
• MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells.

  2014cited by this paper
• Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

  2014cited by this paper
• Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1

  2014cited by this paper
• CD4+ T Effectors Specific for the Tumor Antigen NY-ESO-1 Are Highly Enriched at Ovarian Cancer Sites and Coexist with, but Are Distinct from, Tumor-Associated Treg

  2013cited by this paper
• The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer

  2013cited by this paper
• Effects of CT-Xp Gene Knock down in Melanoma Cell Lines

  2013cited by this paper
• DNA hypomethylation and activation of germline-specific genes in cancer.

  2013cited by this paper
• Centrosomal Localisation of the Cancer/Testis (CT) Antigens NY-ESO-1 and MAGE-C1 Is Regulated by Proteasome Activity in Tumour Cells

  2013cited by this paper
• Preferential expression of cancer/testis genes in cancer stem-like cells: proposal of a novel sub-category, cancer/testis/stem gene.

  2013cited by this paper
• Predictive medicine and esophageal cancer response to preoperative chemotherapy

  2012cited by this paper
• Targeting cancer antigen (MAGE-A4, NY-ESO-1) for immunotherapy

  2012cited by this paper
• T‐cell receptor gene therapy targeting melanoma‐associated antigen‐A4 inhibits human tumor growth in non‐obese diabetic/SCID/γcnull mice

  2012cited by this paper
• High expression of cancer testis antigens MAGE‐A, MAGE‐C1/CT7, MAGE‐C2/CT10, NY‐ESO‐1, and gage in advanced squamous cell carcinoma of the larynx

  2011cited by this paper
• MAGE-A 3 is highly expressed in a subset of colorectal cancer patients

  2011cited by this paper
• Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4

  2011cited by this paper
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

  2011cited by this paper
• MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma

  2011cited by this paper
• Pattern and clinical significance of cancer‐testis gene expression in head and neck squamous cell carcinoma

  2011cited by this paper
• Cancer-testis gene expression profiling in esophageal squamous cell carcinoma: Identification of specific tumor marker and potential targets for immunotherapy

  2011influential reference
• Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy.

  2010cited by this paper
• Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma.

  2010cited by this paper
• Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients

  2010cited by this paper
• Cancer/testis (CT) antigens: Potential targets for immunotherapy

  2009cited by this paper
• Frequent expression of the novel cancer testis antigen MAGE‐C2/CT‐10 in hepatocellular carcinoma

  2009cited by this paper
• The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis.

  2008cited by this paper
• A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

  2007cited by this paper
• Epigenetic control of MAGE gene expression by the KIT tyrosine kinase.

  2007cited by this paper
• The Production of the New

  2007cited by this paper
• De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.

  2006cited by this paper
• Heterogeneous expression of GAGE, NY‐ESO‐1, MAGE‐A and SSX proteins in esophageal cancer: Implications for immunotherapy

  2006cited by this paper
• Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines

  2005cited by this paper
• Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer

  2005cited by this paper
• Cancer/testis antigens, gametogenesis and cancer

  2005cited by this paper
• Distinct Structural TCR Repertoires in Naturally Occurring Versus Vaccine-Induced CD8+ T-Cell Responses to the Tumor-Specific Antigen NY-ESO-1

  2005cited by this paper
• [The expression of 11 cancer/testis (CT) antigen genes in esophageal carcinoma].

  2005cited by this paper
• Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010)

  2005cited by this paper
• Melanoma-Associated Antigens in Esophageal Adenocarcinoma

  2004cited by this paper
• Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants.

  2004cited by this paper
• NY-ESO-1 Expression and Immunogenicity in Esophageal Cancer

  2004influential reference
• The cancer/testis genes: review, standardization, and commentary.

  2004cited by this paper
• Two new tumor‐specific antigenic peptides encoded by gene MAGE‐C2 and presented to cytolytic T lymphocytes by HLA‐A2

  2004cited by this paper
• MAGE-A3 is a frequent tumor antigen of metastasized melanoma

  2004cited by this paper
• Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1

  2004cited by this paper
• Prognostic relevance of MAGE‐A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: A tissue microarray study

  2002cited by this paper
• Tumor‐specific shared antigenic peptides recognized by human T cells

  2002cited by this paper
• The Production of a New MAGE-3 Peptide Presented to Cytolytic T Lymphocytes by HLA-B40 Requires the Immunoproteasome

  2002cited by this paper
• Large Scale Identification of Human Hepatocellular Carcinoma-Associated Antigens by Autoantibodies1

  2002cited by this paper
• Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas

  2001influential reference
• Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours

  2000cited by this paper
• Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library.

  1998cited by this paper
• LAGE‐1, a new gene with tumor specificity

  1998cited by this paper
• Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis.

  1995cited by this paper
• A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

  1991cited by this paper

• Exploring the role and mechanisms of MAGEA4 in tumorigenesis, regulation, and immunotherapy

  2025cites this paper
• Increased MAGE-C Family Gene Expression Levels as a Biomarker of Colon Cancer Through the Demethylation Mechanism

  2024cites this paper
• Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study

  2024cites this paper
• Characterization of PRAME immunohistochemistry reveals lower expression in pediatric melanoma compared to adult melanoma

  2024cites this paper
• Gene-modified T cell therapy for cancer: Current challenges and potential solutions

  2022cites this paper
• Clinical Correlation of Function and TCR vβ Diversity of MAGE-C2–Specific CD8+ T Cell Response in Esophageal Cancer

  2022cites this paper
• Immunological and functional aspects of MAGEA3 cancer/testis antigen.

  2021cites this paper
• Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression

  2020cites this paper
• Emerging roles of the MAGE protein family in stress response pathways

  2020cites this paper
• MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition

  2019cites this paper
• Chapter 2 Immunotherapy for Esophageal Cancer

  2019cites this paper
• Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.

  2019cites this paper
• Immunotherapy for Esophageal Cancer

  2018cites this paper
• Effects of MiR-210 on proliferation, apoptosis and invasion abilities of esophageal cancer cells.

  2018cites this paper
• Dual TGF‐β and PD‐1 blockade synergistically enhances MAGE‐A3‐specific CD8+ T cell response in esophageal squamous cell carcinoma

  2018cites this paper
• MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer

  2018cites this paper
• Melanoma-associated antigen A11 reduces erlotinib and afatinib efficacy in head and neck cancer.

  2017cites this paper
• Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer

  2017cites this paper